8-K Announcements
6Material company update
Mar 31, 2026·SEC
Material company update
Feb 13, 2026·SEC
Material company update
Jan 30, 2026·SEC
IO Biotech, Inc.(IOBT)Earnings, Financials & Key Ratios
IOBT•NASDAQ
$0.01
Price updated Jun 20, 2026
AboutIO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.Show more
- Revenue$0
- EBITDA-$94M-4.0%
- Net Income-$95M-10.9%
- EPS (Diluted)-1.45+26.8%
- ROE-106%-67.5%
IOBT Price & Volume
IO Biotech, Inc. (IOBT) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Threaten Capital Runway Sustainability
Investment Thesis • Updated 2025Q3
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Binary clinical trial failure
"IO Biotech remains a pre-revenue, high-risk clinical-stage entity whose valuation is entirely dependent on the successful progression of its T-win platform. The company faces significant financial pressure as it burns through its remaining $30.7 million cash balance to fund intensive R&D, which reached $13.7 million in 2025Q3. Investors should monitor the high probability of future dilutive capital raises, as the current equity base has eroded to a marginal $0.9 million, leaving little room for operational error."
Verdict Logic
the company's rapid erosion of its asset base from $172.6 million to $40.0 million over two years suggests an unsustainable burn rate that necessitates immediate external financing.
IOBT Growth Metrics
IO Biotech, Inc. (IOBT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM2.2%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM1.46%
Return on Capital
10 Years-392.54%
5 Years-392.54%
3 Years-70.19%
Last Year-103.9%
Peers Comparison
Key metrics vs top competitors for IO Biotech, Inc. (IOBT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.01 | $857.21K | -0.01 | — | — | -106% | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — | |
| $2.83 | $202.47M | -2.01 | — | — | -30.9% | — | |
| $3.03 | $126.18M | -891.18 | 10.37% | 52.16% | — | — | |
| $30.88 | $1.57B | -58.26 | 20% | -4.88% | -4.83% | — | |
| $35.26 | $2.35B | -9.04 | -78.63% | -34596.22% | -50.72% | — |
Compare IOBT vs Peers
IO Biotech, Inc. (IOBT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IOBT SEC Filings & Documents
IO Biotech, Inc. (IOBT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when IOBT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
IOBT Frequently Asked Questions
IO Biotech, Inc. (IOBT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is IOBT profitable?
IO Biotech, Inc. (IOBT) reported a net loss of $88.3M for fiscal year 2024.
Dividend & Returns
What is IOBT's return on equity?
IO Biotech, Inc. (IOBT) has a return on equity (ROE) of -106.0%. Negative ROE indicates the company is unprofitable.
What is IO Biotech, Inc.'s free cash flow?
IO Biotech, Inc. (IOBT) had negative free cash flow of $81.1M in fiscal year 2024, likely due to heavy capital investments.